Skip to main content
Trending
Corporate earningsAi infrastructureEnergy marketsElection litigationAviation safetyCrypto securityAi governanceEnterprise aiPlatform liabilityAvian influenzaClinical trialsFederal debtPresidential runoffRpg developmentSpace debrisAir defenseAutonomous vehiclesBudget crisisBug bountiesEnergy m&aForeign investmentFranchise restructuringGene therapyPandemic treatyTranslation pathwaysUn peacekeepingWeapons testingWeight-space programmingAi copyright lawArchaeological toxicology

full timeline

Next-Generation KRAS Inhibitor Divarasib Shows Superiority Over Approved Drugs in Head-to-Head Lung Cancer Trial

In a head-to-head Phase 3 trial, the experimental targeted therapy divarasib significantly outperformed approved first-generation drugs for previously treated KRAS G12C-mutated non-small cell lung cancer. Patients receiving divarasib lived a median of 17.7 months compared with 12 months for those on standard treatments, establishing a potential new standard of care.

Factlen Newsroom· Updated

Follow Next-Generation KRAS Inhibitor Divarasib Shows Superiority Over Approved Drugs in Head-to-Head Lung Cancer Trial in the Factlen app and get an alert when there is news. Get the app

Illustration: Divarasib demonstrated a 44 percent reduction in the risk of death compared with approved first-generation KRAS G12C inhibitors.From: Next-Generation KRAS Inhibitor Divarasib Cuts Lung Cancer Death Risk by 44 Percent

Share this story

Key numbers

14%
NSCLC cases with KRAS G12C mutation
338
Patients in Krascendo 1 trial
$2.5B
Estimated annual second-line market

From: Next-Generation KRAS Inhibitor Divarasib Shows Superiority Over Approved Drugs in Head-to-Head Lung Cancer Trial

Charts, maps and images

Median overall survival improved by 5.7 months with the next-generation targeted therapy.From: Next-Generation KRAS Inhibitor Divarasib Cuts Lung Cancer Death Risk by 44 Percent ·
Patients receiving divarasib were nearly twice as likely to see their tumors significantly shrink.From: Next-Generation KRAS Inhibitor Divarasib Cuts Lung Cancer Death Risk by 44 Percent ·
Fewer patients discontinued divarasib due to side effects, largely due to lower rates of severe liver toxicity.From: Next-Generation KRAS Inhibitor Divarasib Cuts Lung Cancer Death Risk by 44 Percent ·
Divarasib is a covalent inhibitor that binds to a specific groove on the mutant KRAS protein, locking it in an inactive state and halting cancer growth.From: Next-Generation KRAS Inhibitor Divarasib Shows Superiority Over Approved Drugs in Head-to-Head Lung Cancer Trial ·
Early Phase 1 data suggested divarasib could nearly double the progression-free survival seen with first-generation inhibitors, a signal now validated in Phase 3.From: Next-Generation KRAS Inhibitor Divarasib Shows Superiority Over Approved Drugs in Head-to-Head Lung Cancer Trial ·
Illustration: Divarasib was engineered to bind to the KRAS G12C mutated protein more potently and selectively than earlier drugs.From: Next-Generation KRAS Inhibitor Divarasib Cuts Lung Cancer Death Risk by 44 Percent ·
Show 1 more
Genentech, a member of the Roche Group, led the development of the next-generation inhibitor.From: Next-Generation KRAS Inhibitor Divarasib Shows Superiority Over Approved Drugs in Head-to-Head Lung Cancer Trial ·

Timeline

October 2026

  1. Next-Generation KRAS Inhibitor Divarasib Cuts Lung Cancer Death Risk by 44 Percent

July 2026

  1. Next-Generation KRAS Inhibitor Divarasib Shows Superiority Over Approved Drugs in Head-to-Head Lung Cancer Trial